At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,517 enrolled
Drug / intervention
norelgestromin + ethinyl estradiol; mercilondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17dNorgestimate and Ethinyl Estradiol With the Oral Contraceptive Mercilon.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·interventional·Posted Oct 12, 2005·Updated Jun 8, 2011
In Brief
A Phase 3 clinical trial evaluating norelgestromin + ethinyl estradiol; mercilon for Contraception. Completed, enrolled 1,517 participants.
Detailed Summary
The purpose of the study was to compare the contraceptive efficacy and safety of the transdermal patch to Mercilon.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 1997
Study CompletionMar 1999
First PostedOct 2005
TodayJul 2026
First PostedOct 12, 2005
Enrollment StartOct 1, 1997
Study CompletionMar 1, 1999
TodayJul 2, 2026
Posted 20.7 years ago
Interventions
norelgestromin + ethinyl estradiol; mercilondrug